[Treatment of interdigital tinea pedis].
OBJECTIVE
Local antimycotic therapy of interdigital tinea pedis is widely accepted and efficacious. In Germany at present, the azoles and allylamines--part from the hydroxypyridone derivative ciclopiroxolamine--are the pharmacological agents applied most often. This study focuses on the efficacy of topical therapeutic options in Germany, by regarding the mycological and clinical cure rates of interdigital tinea pedis.


METHODS
Only randomised, double-blind and controlled clinical trials of tinea pedis therapy were selected for the evaluation. Microbiological culture and microscopic information were indispensable criteria for the clinical diagnoses.


RESULTS
The data from 40 randomised clinical trials of azoles and allylamines were included in the analysis. The comparison of azoles with the placebo revealed mycological cure rates between 60 - 91 % (placebo 10 - 67 %) and clinical cure rates between 64 - 95 % (placebo 10 - 63 %). Placebo-controlled trials of allylamines (naftifine and terbinafine) indicated mycological cure rates between 62 - 100 % (placebo 10 - 45 %) and clinical cure rates between 66 - 86 % (placebo 4 - 44 %). Both the azoles and the allylamines were significantly superior to the placebo. Comparative studies between azoles and allylamines occasionally indicated the significantly superior cure rates of allylamines (especially terbinafine). The high cure rates of terbinafine could be detected after therapy duration of merely one week, whereas the azoles have to be applied for four weeks before good efficacy was reached.


CONCLUSIONS
In several trials the allylamines--especially terbinafine--proved superior to the azoles. This may be explained by the fungicidal mode of action of the allylamines and the favourable pharmacokinetic characteristics of terbinafine, in contrast to the fungistatic mechanism of the azoles.
Korting
H C
HC
Klinik und Poliklinik für Dermatologie und Allergologie, Universität München, Munich.
Rychlik
R
R
Pfeil
B
B
D000499:Allylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D009281:Naphthalenes / Q000627:therapeutic use; D009824:Ointments; D016032:Randomized Controlled Trials as Topic; D000077291:Terbinafine; D013997:Time Factors; D014008:Tinea Pedis / Q000188:drug therapy*; D016896:Treatment Outcome
D000935:Antifungal Agents; D009281:Naphthalenes; D009824:Ointments; D000499:Allylamine; C029178:naftifine; D000077291:Terbinafine
Behandlung der Tinea pedis vom interdigitalen Typ. Systematischer Review.